Testosterone shots may ease side effects in prostate cancer survivors
NCT ID NCT03716739
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested whether testosterone replacement therapy could safely improve symptoms like low sex drive and fatigue in 136 men who had their prostate removed for low-risk prostate cancer. Participants received weekly testosterone injections or a placebo for 12 weeks. The study tracked PSA levels and sexual activity to see if the treatment helped without causing cancer to return.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
testosterone cypionate (Depo-Testosterone)
What this could lead to
If it works, this could offer a way to ease sexual and fatigue-related symptoms in prostate cancer survivors without raising short-term cancer recurrence risk.
What could go wrong
This is a small, early-phase trial with only 136 men who had very low-risk cancer. Testosterone may still trigger cancer growth in other patients, and long-term safety is not established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States